Sugi Predict

Sugi Predict / Targets / CDYL

CDYL

Chromodomain Y-like protein · Q9Y232 · CDYL on Sugi Atlas →

5,919 patent compounds predicted against CDYL, 3,216 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2950965 SCHEMBL2950965 0.70 8/20
SCHEMBL4246933 SCHEMBL4246933 0.52 8/20
SCHEMBL2953262 SCHEMBL2953262 0.50 8/20
SCHEMBL4242148 SCHEMBL4242148 0.56 7/20
SCHEMBL3706421 SCHEMBL3706421 0.50 7/20
Bromide Bromide (SCHEMBL3845737) 0.52 6/20
Bromide Bromide (SCHEMBL3845745) 0.48 6/20
SCHEMBL2829735 SCHEMBL2829735 0.80 5/20
SCHEMBL624198 SCHEMBL624198 0.49 5/20
SCHEMBL2606334 SCHEMBL2606334 0.48 5/20
Bromide Bromide (SCHEMBL3853584) 0.47 5/20
SCHEMBL1063151 SCHEMBL1063151 0.43 5/20
SCHEMBL1061180 SCHEMBL1061180 0.42 5/20
SCHEMBL3746585 SCHEMBL3746585 0.41 5/20
SCHEMBL3746589 SCHEMBL3746589 0.41 5/20
SCHEMBL2403057 SCHEMBL2403057 0.64 4/20
SCHEMBL3026762 SCHEMBL3026762 0.55 4/20
SCHEMBL2953037 SCHEMBL2953037 0.50 4/20
Bromide Bromide (SCHEMBL3853590) 0.48 4/20
SCHEMBL2540729 SCHEMBL2540729 0.47 4/20

Clinical trials — most relevant to CDYL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer PHASE1/PHASE2WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Eating Behaviour in Crohn's Disease nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Immunophenotyping and Xist Gene in AML nanUNKNOWN
Genetic Studies Spermatogenic Failure nanCOMPLETED
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes nanACTIVE_NOT_RECRUITING
Study of the Sex Differences in Inflammatory Diseases in Children nanUNKNOWN
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study nanCOMPLETED
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science nanRECRUITING
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Genomic Imprinting Testing for Diagnosis of Bladder Cancer nanUNKNOWN
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort Study nanCOMPLETED
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders nanNOT_YET_RECRUITING
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer nanCOMPLETED
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Patients With RETT Syndrome nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Genomic Study of Congenital Malformation nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDYL binder may also engage these)

ProteinNameSimilarity
Q6AYK9 — 1.000 Q6AYK9 →
Q9WTK2 — 1.000 Q9WTK2 →
Q9D5D8 — 0.994 Q9D5D8 →
Q5TKR9 — 0.993 Q5TKR9 →
Q9Y6F7 — 0.993 Q9Y6F7 →
CDY1; CDY1B Testis-specific chromodomain protein Y 1 0.993 landscape →
G5EFD2 — 0.992 G5EFD2 →
Q6E3D4 — 0.992 Q6E3D4 →
Q8BMD7 — 0.991 Q8BMD7 →
Q8WML3 — 0.991 Q8WML3 →
B3M301 — 0.991 B3M301 →
KAT6B Histone acetyltransferase KAT6B 0.991 landscape →
B4NBP4 — 0.991 B4NBP4 →
KMT5B Histone-lysine N-methyltransferase KMT5B 0.991 landscape →
Q9XYB7 — 0.990 Q9XYB7 →
Q8C0I4 — 0.990 Q8C0I4 →
Q1LYM3 — 0.990 Q1LYM3 →
Q5HZN1 — 0.990 Q5HZN1 →
Q8BZ21 — 0.989 Q8BZ21 →
Q9H329 — 0.989 Q9H329 →
Q99PI5 — 0.989 Q99PI5 →
Q92539 — 0.989 Q92539 →
P06536 — 0.989 P06536 →
O70445 — 0.989 O70445 →
A6QP06 — 0.989 A6QP06 →
O43078 — 0.989 O43078 →
Q9VFH6 — 0.989 Q9VFH6 →
G5EGA3 — 0.989 G5EGA3 →
P34489 — 0.989 P34489 →
Q08639 — 0.989 Q08639 →